Cargando…

Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study()

INTRODUCTION: A mass vaccination campaign against SARS-CoV-2 was initiated in European countries on December 27, 2020. This study compared the antibody response in a sample of healthcare workers (HCWs) who, after the first dose of the BNT162b2 mRNA vaccine, were infected with SARS-CoV-2 (infection g...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanizzi, Pasquale, Larocca, Angela Maria Vittoria, Martinelli, Andrea, Soldano, Savino, Dell'Aera, Maria, Migliore, Giovanni, Germinario, Cinzia Annatea, Vimercati, Luigi, Tafuri, Silvio, Bianchi, Francesco Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847089/
https://www.ncbi.nlm.nih.gov/pubmed/35190212
http://dx.doi.org/10.1016/j.vaccine.2022.02.002
_version_ 1784651974043500544
author Stefanizzi, Pasquale
Larocca, Angela Maria Vittoria
Martinelli, Andrea
Soldano, Savino
Dell'Aera, Maria
Migliore, Giovanni
Germinario, Cinzia Annatea
Vimercati, Luigi
Tafuri, Silvio
Bianchi, Francesco Paolo
author_facet Stefanizzi, Pasquale
Larocca, Angela Maria Vittoria
Martinelli, Andrea
Soldano, Savino
Dell'Aera, Maria
Migliore, Giovanni
Germinario, Cinzia Annatea
Vimercati, Luigi
Tafuri, Silvio
Bianchi, Francesco Paolo
author_sort Stefanizzi, Pasquale
collection PubMed
description INTRODUCTION: A mass vaccination campaign against SARS-CoV-2 was initiated in European countries on December 27, 2020. This study compared the antibody response in a sample of healthcare workers (HCWs) who, after the first dose of the BNT162b2 mRNA vaccine, were infected with SARS-CoV-2 (infection group) with the response in a control group of HCWs immunized with two doses (vaccine group). METHODS: This two-arm observational cohort study was carried out using routine health surveillance data obtained from HCWs at Bari Policlinico General Hospital (Italy). The antibody response was determined infection group and vaccine group. RESULTS: Among the 100 HCWs, 25 (25.0%) were in the infection group and 75 (75.0%) in the full-vaccine group. At the serological evaluation, all of the HCWs tested positive, with a geometric mean titer (GMT) of 7106.8 (95 %CI = 5628.5–8973.4) and a statistically significant difference (p < 0.0001) between the infection group (GMT = 2139.7; 95 %CI = 1310.4–3493.6) and the vaccine group (GMT = 10603.6; 95 %CI = 8698.0–12926.8). DISCUSSION: Our results shed light on the vaccine response of individuals in different risk categories. It also emphasizes the need for the continued use by HCWs of PPE and good practices during the window between the first and second anti-SARS-CoV-2 vaccinations.
format Online
Article
Text
id pubmed-8847089
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88470892022-02-16 Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study() Stefanizzi, Pasquale Larocca, Angela Maria Vittoria Martinelli, Andrea Soldano, Savino Dell'Aera, Maria Migliore, Giovanni Germinario, Cinzia Annatea Vimercati, Luigi Tafuri, Silvio Bianchi, Francesco Paolo Vaccine Article INTRODUCTION: A mass vaccination campaign against SARS-CoV-2 was initiated in European countries on December 27, 2020. This study compared the antibody response in a sample of healthcare workers (HCWs) who, after the first dose of the BNT162b2 mRNA vaccine, were infected with SARS-CoV-2 (infection group) with the response in a control group of HCWs immunized with two doses (vaccine group). METHODS: This two-arm observational cohort study was carried out using routine health surveillance data obtained from HCWs at Bari Policlinico General Hospital (Italy). The antibody response was determined infection group and vaccine group. RESULTS: Among the 100 HCWs, 25 (25.0%) were in the infection group and 75 (75.0%) in the full-vaccine group. At the serological evaluation, all of the HCWs tested positive, with a geometric mean titer (GMT) of 7106.8 (95 %CI = 5628.5–8973.4) and a statistically significant difference (p < 0.0001) between the infection group (GMT = 2139.7; 95 %CI = 1310.4–3493.6) and the vaccine group (GMT = 10603.6; 95 %CI = 8698.0–12926.8). DISCUSSION: Our results shed light on the vaccine response of individuals in different risk categories. It also emphasizes the need for the continued use by HCWs of PPE and good practices during the window between the first and second anti-SARS-CoV-2 vaccinations. The Authors. Published by Elsevier Ltd. 2022-03-15 2022-02-16 /pmc/articles/PMC8847089/ /pubmed/35190212 http://dx.doi.org/10.1016/j.vaccine.2022.02.002 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Stefanizzi, Pasquale
Larocca, Angela Maria Vittoria
Martinelli, Andrea
Soldano, Savino
Dell'Aera, Maria
Migliore, Giovanni
Germinario, Cinzia Annatea
Vimercati, Luigi
Tafuri, Silvio
Bianchi, Francesco Paolo
Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study()
title Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study()
title_full Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study()
title_fullStr Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study()
title_full_unstemmed Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study()
title_short Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study()
title_sort immune response to one dose of bnt162b2 mrna covid-19 vaccine followed by sars-cov-2 infection: an italian prospective observational study()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847089/
https://www.ncbi.nlm.nih.gov/pubmed/35190212
http://dx.doi.org/10.1016/j.vaccine.2022.02.002
work_keys_str_mv AT stefanizzipasquale immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT laroccaangelamariavittoria immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT martinelliandrea immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT soldanosavino immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT dellaeramaria immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT miglioregiovanni immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT germinariocinziaannatea immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT vimercatiluigi immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT tafurisilvio immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy
AT bianchifrancescopaolo immuneresponsetoonedoseofbnt162b2mrnacovid19vaccinefollowedbysarscov2infectionanitalianprospectiveobservationalstudy